ConductScience.org, home

Paper709555

In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.

Johnson RK and 3 others. Cancer Treat Rep, 1978. Cited by 258 papers, by iCite.

Cite this record

ConductScience Library. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Papers, record 709555. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/709555

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
258
iCite
Relative citation ratio, by iCite
8.53
iCite
Revised in PubMed
2013-11-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Johnson RKR K
2Chitnis MPM P
3Embrey WMW M
4Gregory EBE B

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
Leukemia, ExperimentalMajor topic
Animals
Antibiotics, Antineoplastic
Antineoplastic Agents
Cell Line
DNA, Neoplasm
Daunorubicin
Drug Resistance
Mice
RNA, Neoplasm

Source PubMed

Download CSV of topics

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 258 citations.

PMIDTitleJournalYearIn PapersSource
40848933Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future.J Mol Biol2026https://conductscience.org/library/papers/40848933PubMed
29983877Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.Oncotarget2018https://conductscience.org/library/papers/29983877PubMed
22791660A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.Oncotarget2012https://conductscience.org/library/papers/22791660PubMed
12003193Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.Invest New Drugs2002https://conductscience.org/library/papers/12003193PubMed
10206276In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.Br J Cancer1999https://conductscience.org/library/papers/10206276PubMed
9764579Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.Br J Cancer1998https://conductscience.org/library/papers/9764579PubMed
9740539Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.Invest New Drugs1998https://conductscience.org/library/papers/9740539PubMed
8913834Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.Invest New Drugs1996https://conductscience.org/library/papers/8913834PubMed
8422694Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8422694PubMed
7841045Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitising agent.Br J Cancer1995https://conductscience.org/library/papers/7841045PubMed
7513620V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/7513620PubMed
7296754Experimental in vivo cross-resistance of vinca alkaloid drugs.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7296754PubMed
7105379Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105379PubMed
6943568Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6943568PubMed
6938517Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.J Cancer Res Clin Oncol1980https://conductscience.org/library/papers/6938517PubMed
6498081Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.Br J Cancer1984https://conductscience.org/library/papers/6498081PubMed
6149230Cells resistant to cytotoxic drugs are recognized by monoclonal antibody.J Clin Immunol1984https://conductscience.org/library/papers/6149230PubMed
4006047Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4006047PubMed
3886588The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.Invest New Drugs1985https://conductscience.org/library/papers/3886588PubMed
3858013Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3858013PubMed

See all 39 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/709555

GET https://conductscience.org/api/papers/v1/709555/cited_by?page=2